Clinical Cancer Research Targets AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chotteau-Lelièvre, A.
Right arrow Articles by Peyrat, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chotteau-Lelièvre, A.
Right arrow Articles by Peyrat, J.-P.
Clinical Cancer Research Vol. 10, 7297-7303, November 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers

Anne Chotteau-Lelièvre1,2, Françoise Révillion3, Valérie Lhotellier3, Louis Hornez3, Xavier Desbiens2, Véronique Cabaret4, Yvan de Launoit1,5 and Jean-Philippe Peyrat3

1 Unité Mixte de Recherche 8117-Centre National de la Recherché Scientifique, Régulation Transcriptionnelle au cours de la Tumorigenèse Mammaire, Institut de Biologie de Lille, Institut Pasteur de Lille, Lille Cédex, France; 2 Laboratoire de Biologie du Développement, UPRES 1033, Université des Sciences et Techniques de Lille-Flandres-Artois, Villeneuve d’Ascq Cédex, France; 3 Laboratoire d’Oncologie Moléculaire Humaine and 4 Laboratoire de Cytologie et Anatomie Pathologiques, Centre Oscar Lambret, 59020 Lille Cédex, France; and 5 Laboratoire de Virologie Moléculaire-Faculté de Médecine, Université Libre de Brussels, Brussels, Belgium

We measured the expression of ERM gene, a nuclear transcription factor belonging to the ets family, in a series of 364 unselected primary breast cancers from patients who underwent locoregional surgery in the Centre Oscar Lambret between May 1989 and December 1991. The expression of ERM was quantified with a real-time one-step reverse transcription-PCR assay based on the 5'-nuclease activity of the TaqDNA polymerase and with an Abi Prism 7700 Sequence Detector System (Applied Biosystems, Courtaboeuf, France). ERM was positively correlated (Spearman test) to epidermal growth factor receptor (EGFR; P < 0.001, r = 0.296) and to histoprognostic grading (P = 0.044, r = 0.112), whereas it was negatively correlated to estradiol receptors (P = 0.019, r = -0.124), HER3 (c-erbB-3; P = 0.01, r = –0.135), and HER4 (c-erbB-4; P = 0.003, r = –0.154). Using the {chi}2 test, a positive relationship was found between the expression of ERM and EGFR ({chi}2 = 7.795, P = 0.007). In overall survival studies, Cox univariate analyses demonstrated a prognostic value of ERM (P = 0.006; risk ratio, 2.95) besides the classical prognostic factors histoprognostic grading, node involvement, tumor size, estradiol receptors, progesterone receptors, EGFR, HER3, and HER4. In multivariate analyses, ERM preserved its prognostic value (P = 0.004; risk ratio, 3.779) together with histoprognostic grading, tumor size, estradiol receptors, and progesterone receptors. In relapse-free survival studies, univariate analyses demonstrated that histoprognostic grading, node involvement, tumor size, and HER4 were prognostic factors. These parameters, except histoprognostic grading, retained their prognostic value in multivariate analyses. This study demonstrates for the first time that ERM gene expression is an independent adverse prognostic factor for overall survival in breast cancer patients.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
V. Firlej, F. Ladam, G. Brysbaert, P. Dumont, F. Fuks, Y. de Launoit, A. Benecke, and A. Chotteau-Lelievre
Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription
J. Cell Sci., October 15, 2008; 121(20): 3393 - 3402.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. E. Witek, K. Nielsen, R. Walters, T. Hyslop, J. Palazzo, S. Schulz, and S. A. Waldman
The Putative Tumor Suppressor Cdx2 Is Overexpressed by Human Colorectal Adenocarcinomas
Clin. Cancer Res., December 15, 2005; 11(24): 8549 - 8556.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Firlej, B. Bocquet, X. Desbiens, Y. de Launoit, and A. Chotteau-Lelievre
Pea3 Transcription Factor Cooperates with USF-1 in Regulation of the Murine bax Transcription without Binding to an Ets-binding Site
J. Biol. Chem., January 14, 2005; 280(2): 887 - 898.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.